ARTCLINE successfully completes capital increases of EUR 4.4 million
With the additional funds, ARTCLINE will finance the further execution of the randomized, controlled clinical trial ReActIF-ICE with more than 100 patients with septic shock. The study is currently being conducted in intensive care units in 12 German hospitals and is intended to show not only the safety but also the efficacy of the ARTICE® therapy.
"Sepsis stands as the third leading cause of death in
About ARTCLINE GmbH
ARTCLINE GmbH was founded in 2007 as a spin-off from the University of Rostock. The company develops a novel immune cell-based extracorporeal sepsis therapy for patients worldwide. Septic shock is still an immense challenge for our health care system. It is caused by immune dysfunction in the context of severe infections.
The ARTICE® therapy uses immune cells from healthy blood donors to temporarily take over partial functions and also reactivate the patient's own immune system.
Media Contact:
Dr.
CEO
Phone: +49 (0)381 440 7030
E-Mail: [email protected]
View original content:https://www.prnewswire.com/news-releases/artcline-successfully-completes-capital-increases-of-eur-4-4-million-302097936.html
SOURCE ARTCLINE GmbH
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NAPA Anesthesia White Paper: Changing the Schedule Won't Fix Your Anesthesiology Department
- 53% of Organizations Struggle to Translate Business Context Into AI Despite Rising AI Investment
- Urban Arrow Expands into the Longtail Segment with the Breeze, Bringing Its Proven Safety and Design to the Leading Cargo Bike Format
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share